• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
    • Venture Capital
  • About
  • Contact

FDA Approves First Plasma Therapy For Houston Methodist COVID-19 Patient

March 30, 2020 By admin Leave a Comment

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient. This treatment was fast-tracked to the bedside over the weekend as the death toll in the COVID-19 pandemic soared to more than 2,000 people across the United States, with more than 100,000 Americans sick from the virus.

Houston Methodist physician scientists began recruiting blood plasma donors on Friday from among the approximately 250 patients who have tested positive for the COVID-19 virus at Houston Methodist hospitals. Willing donors were immediately identified, who each give a quart of blood plasma in a procedure much like donating whole blood. Plasma from someone who has recovered from COVID-19 contains antibodies made by the immune system and used to kill the virus. Transfusing this antibody-rich plasma into a COVID-19 patient – a patient still fighting the virus – may transfer the power of the antibodies into a healing, possibly life-saving therapy.

The first recovered COVID-19 patient to donate plasma was an individual from the Houston metropolitan area who has been in good health for more than two weeks. The plasma was transfused into a COVID-19 patient on Saturday evening at Houston Methodist Hospital

Known as convalescent serum therapy, the concept dates back more than a century, when similar treatments were used during the Spanish flu pandemic of 1918, a diphtheria outbreak in the 1920s, a flesh-eating bacteria epidemic in the 1930s, and during other outbreaks of infectious diseases. While literature abounds on the theory that immunity can be transferred from a healthy individual to a sick individual using convalescent plasma, results have varied. A description of the treatment of five patients in China was published this week in the Journal of the American Medical Association, suggesting that the treatment was beneficial.

“Here at Houston Methodist, we have the capability, the expertise and the patient base from our health care system, and we feel obligated to try this therapy,” said Houston Methodist President and CEO Marc Boom.

“There is so much to be learned about this disease while it’s occurring,” he said. “If an infusion of convalescent serum can help save the life of a critically ill patient, then applying the full resources of our blood bank, our expert faculty, and our academic medical center is incredibly worthwhile and important to do.”

Houston Methodist recruitment began as soon as the FDA issued regulatory guidelines for the study earlier last week. Physician scientists at Houston Methodist already had designed and validated a COVID-19 molecular test two months ago and were prepared to begin collecting data when COVID-19 patients started arriving. The Houston Methodist IRB and regulatory affairs experts reviewed the treatment protocol rapidly and secured the FDA approval this weekend.

In New York City earlier this week, Gov. Andrew Cuomo announced that patient recruitment for plasma donations would begin in a matter of days and initially would focus on the heavily hit New York City suburb of New Rochelle, NY.

Eric Salazar, M.D., Ph.D., principal investigator and a physician scientist in the Department of Pathology and Genomic Medicine at the Houston Methodist Hospital and Research Institute, said a review of COVID-19 patients’ charts indicates that nearly two-thirds of the patients may meet the criteria to donate plasma. Patients with critical underlying conditions and advanced age will not be eligible to donate.

Under FDA guidelines, Houston Methodist’s convalescent serum therapy treatment is classified as an emergency investigational new drug protocol (eIND) that requires FDA approval for each patient infused with donated convalescent serum. Houston Methodist physician scientists will seek additional FDA approval for follow-up studies, possibly a multicenter national trial on the effectiveness of convalescent serum therapy against the COVID-19 virus.

The process for donating plasma is similar to donating blood and takes about an hour. Plasma donors are hooked up to a small device that removes plasma while simultaneously returning red blood cells to their bodies. Unlike regular blood donation in which donors have to wait for red blood cells to replenish between donations, plasma can be donated more frequently, as often as twice a week.

“Convalescent serum therapy could be a vital treatment route, because unfortunately there is relatively little to offer many patients except supportive care, and the ongoing clinical trials are going to take a while. We don’t have that much time,” Salazar said.

SOURCE Houston Methodist
http://www.methodisthealth.com

Filed Under: Tech Tagged With: COVID-19, Plasma Therapy

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

AI reality vs. myth: predictions for 2024
Cloudflare is introducing the concept of the “connectivity cloud”
Robotic Revolution: Japan’s Surging Industrial Robot Market and China’s Dominance
China’s Poaching of Water Technologies from the West: A Serious Concern
Market Scenario of China Banning Exports of Rare Earth Materials and Electric Batteries
Navigating Markets through a 4-Dimensional Research Data Model
A Markov Chain-Based Approach for Forecasting Emerging Technologies: An Extended Analysis

Market Research Media

The Evolution of RSS Feeds: A Media Analyst’s Perspective
AI-Enhanced 4-Dimensional Market Dynamics Analysis: Unveiling Trends, Segmentation, Behavior, and Evolution through Markov Chain Modeling
Autotutoring Market: Personalized Learning and Technological Innovation at the Forefront
Integration of Generative AI and Large Language Models for Enterprises
The Decline of Chinese Media Under Authoritarian Rule: Economic Implications
Algorithmic Bias in Media Recommendation Systems: Unveiling Challenges and Pursuing Fairness
U.S. Federal IT Market Forecast

Secondary Sidebar

Tech Events

Smart City Expo 2023 Reshapes Urban Futures with Unprecedented Participation and Innovation Showcase
SAP SBN User Conference is taking place on October 17-18, 2023 in Oslo, Norway
2023 European Conference on Optical Communication (ECOC) in Glasgow, Scotland, October 2-4, 2023
Bloomberg Technology Summit, October 24t, 2023, London
Imagine 2023, Edge AI Conference, September 27, 2023, Computer History Museum, Mountain View, California

Venture Capital

Silverflow Secures €15 Million Investment to Revolutionize Global Payment Processing
Myrror Security, an Israeli company specializing in application security for organizations using open-source packages, has officially launched with $6 million in seed funding
Iron Nation Launches Volunteer Emergency Impact Fund to Support Israeli Start-ups Affected by Recent Conflict
UnitX, a robotics company specializing in AI vision systems, secures $5 Million
UserEvidence, a customer voice platform, secured $9 million in Series A funding

Footer

Recent Posts

  • IBM Quantum Summit Unveils Breakthroughs: IBM Quantum Heron and System Two
  • Apple has announced the winners of the 2023 App Store® Awards
  • Aalyria and Airbus Collaborate on High-Speed Aerial and Spaceborne Networks
  • Entrepreneurship Program at Argonne National Laboratory Opens Applications for Startups
  • Toyota is nearing mass production of solid-state batteries
  • Cloudflare and Meta Partner to Democratize Access to Llama 2 Open Source Large Language Model (LLM)
  • Bridging the Semiconductor Workforce Gap: Intel’s Innovative Educational Initiatives
  • German Government and Bavaria Invest €300M in ams OSRAM Semiconductor Tech
  • Innovative Ship Concept: Providing Zero-Carbon Nuclear Energy for Defense and Disaster Relief
  • Linux Foundation Launches OpenTofu: A New Open Source Alternative to Terraform

App Coding

Cybertech 2023 in Tel Aviv: Navigating the Challenges of App Security
App Development: Building Cross-Platform Mobile Apps with React Native
What are implications of rewarding developers basing on number of lines of code?
The Benefits of Cross-Platform Mobile App Development
How to teach yourself app coding

API Coding

Streamlining Your Workflow with API Integrations: Benefits and Best Practices
Implications of Twitter's Free API Shutdown for Developers and Businesses
Creating an API that generates a description of an image using ChatGPT
How to Build API in Next.js
How to Secure Your API: Best Practices for API Authentication and Authorization

Blockchaining

Building a Decentralized VPN Using Blockchain Technology
Asia’s Premier Web3 Conference TOKEN2049 Returns to Singapore in September 2023
Are blockchain transactions traceable?
Blockchain topics to be covered at DLD 2023
Creating a Unique and Valuable Non-Fungible Token (NFT): A Step-by-Step Guide

Calendarial

Comic Con, Taking Place at the Los Angeles Convention Center, December 1-3, 2023
Smart City Expo 2023: “The New Urban Era” in a Record-Breaking Edition, November 7-9, 2023, Barcelona
Apple: “Scary Fast” virtual event, October 30, 2023
Our hearts go out to the people of Israel
The 30th annual RegTech Convention, 21-22 November 2023

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT